459 related articles for article (PubMed ID: 20035186)
1. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.
Center B; Petty WJ; Ayala D; Hinson WH; Lovato J; Capellari J; Oaks T; Miller AA; Blackstock AW
J Thorac Oncol; 2010 Jan; 5(1):69-74. PubMed ID: 20035186
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H
J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213
[TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA
J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Kelly K; Chansky K; Gaspar LE; Albain KS; Jett J; Ung YC; Lau DH; Crowley JJ; Gandara DR
J Clin Oncol; 2008 May; 26(15):2450-6. PubMed ID: 18378568
[TBL] [Abstract][Full Text] [Related]
5. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.
Socinski MA; Rosenman JG; Schell MJ; Halle J; Russo S; Rivera MP; Clark J; Limentani S; Fraser R; Mitchell W; Detterbeck FC
Cancer; 2000 Aug; 89(3):534-42. PubMed ID: 10931452
[TBL] [Abstract][Full Text] [Related]
6. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
7. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
[TBL] [Abstract][Full Text] [Related]
8. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T
J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
Stinchcombe TE; Lee CB; Moore DT; Rivera MP; Halle J; Limentani S; Rosenman JG; Socinski MA
J Thorac Oncol; 2008 Nov; 3(11):1279-85. PubMed ID: 18978563
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
[TBL] [Abstract][Full Text] [Related]
12. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiation therapy with docetaxel/cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer: results of a phase I study.
Huber RM; Borgmeier A; Flentje M; Willner J; Schmidt M; Manegold C; Bramlage P; Debus J
Clin Lung Cancer; 2010 Jan; 11(1):45-50. PubMed ID: 20085867
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial.
Poudenx M; Bondiau PY; Chamorey E; Venissac N; Otto J; Pourel N; Castelnau O; Tessier E; De Surmont Salasc B; Berdah JF; Pop D; Michel C; Mouroux J
Oncology; 2012; 83(6):321-8. PubMed ID: 22986621
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.
Yamamoto N; Nishimura Y; Nakagawa K; Matsui K; Fukuoka M
Cancer Chemother Pharmacol; 2006 Sep; 58(3):285-91. PubMed ID: 16416334
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer.
Wu HG; Bang YJ; Choi EK; Ahn YC; Kim YW; Lim TH; Suh C; Park K; Park CI
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):75-80. PubMed ID: 11777624
[TBL] [Abstract][Full Text] [Related]
17. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
[TBL] [Abstract][Full Text] [Related]
19. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.
Wirth LJ; Lucca J; Ostler P; Fidias P; Lynch C; Jänne PA; Herbst RS; Johnson BE; Sugarbaker DJ; Mathisen DJ; Lukanich JM; Choi NC; Berman SM; Skarin AT
Clin Cancer Res; 2003 May; 9(5):1698-704. PubMed ID: 12738723
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]